Is Tvardi Therapeutics, Inc. technically bullish or bearish?

Sep 20 2025 08:34 PM IST
share
Share Via
As of October 1, 2023, Tvardi Therapeutics, Inc. has a bullish technical stance with moderate strength, supported by positive MACD and moving averages, and has outperformed the S&P 500 with a 1-year return of 276.26% compared to 17.14%.
As of 1 October 2023, the technical stance for Tvardi Therapeutics, Inc. is bullish with moderate strength. The weekly MACD is bullish, supported by bullish signals from the Bollinger Bands and daily moving averages. The monthly MACD is mildly bullish, while the KST shows a mixed view with a mildly bearish weekly signal but bullish monthly. Dow Theory and OBV both indicate a mildly bullish stance on a weekly and monthly basis.

In terms of performance, the stock has significantly outperformed the S&P 500 across multiple periods, with a 1-year return of 276.26% compared to the S&P 500's 17.14%.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Is Tvardi Therapeutics, Inc. overvalued or undervalued?
Sep 20 2025 06:51 PM IST
share
Share Via
Tvardi Therapeutics Hits New 52-Week High at $40.77
Sep 19 2025 01:19 PM IST
share
Share Via
Tvardi Therapeutics Hits New 52-Week High at $39.04
Sep 18 2025 01:31 PM IST
share
Share Via